Nublexa 40mg Tablet

• Colorectal cancer
  
• Gastrointestinal stromal tumors (GIST)
  
• Liver cancer (hepatocellular carcinoma)
  

Side effects are unwanted symptoms that can occur from any medical treatment. Like other medications, the Nublexa 40mg Tablet can also have adverse effects on the body, most of which resolve without the need for medical attention.

Some common side effects include:

• Infection
  
• Low blood platelets
  
• Anemia (low number of red blood cells)
  
• Rash
  
• Weakness
  
• Vomiting
  
• Pain
  
• Nausea
  
• Fever
  
• Diarrhea
  
• High blood pressure
  
• Decreased appetite
  
• Mucosal inflammation
  
• Stomatitis (Inflammation of the mouth)
  
• Increased liver enzymes
  
• Weight loss
  
• Voice change
  
• Bilirubin in urine

Inform your doctor immediately if you experience any persistent or unusual side effect.

• The dosage and duration of treatment with Nublexa 40mg Tablet are determined by the doctor as per the patient's health condition and other medical factors.
• This tablet should be taken at fixed time every day after a light or low-fat meal.
• Swallow the tablets whole with water and don't chew, crush, or break them.
• Do not change or stop the dose without informing your doctor.

• Nublexa 40mg Tablet contains Regorafenib as its active ingredient, which is a multikinase inhibitor.
• It works by blocking the action of various enzymes that help in cancer cell multiplication and growth.
• By inhibiting these signals, it slows down the progression of cancer and reduces blood supply to the tumor (anti-angiogenic effect), which leads to a reduction in the tumor size.

• Strumberg, D., Scheulen, M. E., Schultheis, B., Richly, H., Frost, A., Büchert, M., ... & Mross, K. (2012). Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. British journal of cancer, 106(11), 1722-1727.
  
• Ettrich, T. J., & Seufferlein, T. (2018). Regorafenib. Small molecules in oncology, 45-56.
  
• Heo, Y. A., & Syed, Y. Y. (2018). Regorafenib: a review in hepatocellular carcinoma. Drugs, 78(9), 951-958.
  
• Dhillon, S. (2018). Regorafenib: a review in metastatic colorectal cancer. Drugs, 78(11), 1133-1144.Granito, A., Forgione, A., Marinelli, S., Renzulli, M., Ielasi,
• L., Sansone, V., ... & Tovoli, F. (2021). Experience with regorafenib in the treatment of hepatocellular carcinoma. Therapeutic Advances in Gastroenterology, 14, 17562848211016959.
  
• Strumberg, D., & Schultheis, B. (2012). Regorafenib for cancer. Expert opinion on investigational drugs, 21(6), 879-889.​